Figure 1 | Scientific Reports

Figure 1

From: Oncogenic miR-9 is a target of erlotinib in NSCLCs

Figure 1

Erlotinib downregulated miR-9 expression.

(A) A549 cells were treated with erlotinib 2.5, 5, 10 μmol/L for 72 h. (B) HCC827 cells were treated with erlotinib 50 nmol/L and Calu-1, H157, H460 cells were treated with erlotinib 5 μmol/L for 24 h. The total RNAs were purified and subjected to qRT-PCR assay. Columns, means of three replicate determinations; bars, SD. *P < 0.05.

Back to article page